Managing Our business Responsibly
 

By conducting our business responsibly and transparently, we establish ourselves as the leader and partner of choice in managing kidney care in a value based system. We must continuously create clinical value for our partners and patients that translates to economic value for all of us. Our approach is guided by evolving best practices and feedback from our stakeholders on topics identified as vital to our shared success.

financial management


100%

of Fresenius Kidney Care facilities maintained 5-Diamond status for patient safety for the 6th consecutive year.

financial management


26,500+

U.S. employees and contractors completed OSHA product safety training.

financial management


11,000+

diverse suppliers supported.

Governance

financial management


global operations and policies


We are a wholly owned subsidiary of Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases. Key information on our global operations includes: 

Sustainability reports and indices:


We develop policies and targets to drive progress on our commitments. Key global policies and standards are found on Fresenius Medical Care’s website, and include, but are not limited to:

  • Code of Ethics and Business Conduct 

  • Company Position Statement on Bioethics 

  • Compliance Brochure for Our Business Partners

  • Conflict Minerals Policy Statement  

  • Environmental Policy 

  • Global Occupational Health & Safety Policy 

  • Group Tax Policy 

  • Human Rights, Workplace Rights, and Labor and Employment Principles 

  • Privacy Policy

  • Statement on Gender Equality

  • Statement on Political Engagement

  • Supplier Code of Conduct 

Responsible Management

Patient Safety

PROVIDING TESTING FOR COVID-19

disaster response

Employee Health and Safety

COMPLIANCE PROGRAM

GLOBAL SUPPLIER CODE OF CONDUCT

Supplier Diversity

financial management

DATA PRIVACY AND CYBERSECURITY

In 2018 Fresenius Medical Care North America established our Information Security Office and appointed a chief information security officer (CISO) who partners with executive leadership to deploy trusted solutions that strengthen and streamline our approach to data privacy and cybersecurity. In 2021, Fresenius Medical Care expanded its commitment to improving cybersecurity resilience and hired their first global CISO. The global CISO will drive an Information Security and IT Privacy Assurance program that integrates against our global corporate needs.

POLITiCAL ADVOCACY

Research and innovation

 

 

 

Artificial Intelligence Solutions in Nephrology 


Artificial Intelligence (AI), data science, and advanced analytics are helping to make advances in the treatment of chronic kidney disease and across healthcare at large. By leveraging big data to accelerate AI solutions for kidney disease, researchers, data scientists, and practitioners are developing clinical tools that enhance patient care. Throughout Fresenius Medical Care, we’re using advanced analytics to support clinical decision-making with a suite of more than 20 different models. Some of these AI-based tools include models to reduce hospitalizations, provide insights on in-center dialysis patients who would do well on home modalities, identify patient acuity according to social workers and dietitians, and predict peritoneal dialysis technique failure.

LEARN MORE

 

renal therapies group (RTG)


Our Clinical Research and Medical Affairs team co-authored 18 scientific and medical publications in support of our products. In addition, we completed an open-label clinical study to assess the performance of the dialyzer with Endexo™ in patients with end stage renal disease. This study saw heparin-free hemodialysis achieved in 80 to 96 percent of dialysis sessions using a circuit with the dialyzer with EndexoTM, Citrasate dialysate, and two different bloodlines.

 

frenova renal research


In the world of kidney disease and related disorders, Frenova Renal Research is a site management organization and the largest global network of investigators, chronic kidney disease (CKD) patients, end stage renal disease (ESRD) patients, and data assets for clinical trials. In 2021, Frenova enrolled 2,092 patients across 49 studies, a 266 percent increase in patients from 2020.

 

renal research institute


Our Renal Research Institute (RRI) is committed to helping people with chronic kidney disease and end stage kidney disease lead fuller, more active, and vibrant lives. We strive to achieve this goal by not only offering the best care possible, but also by giving our patients an option to enroll in research studies. We have continued to focus on the COVID-19 pandemic, and in 2021 RRI had its COVID-19 research published in 10 peer-reviewed publications and helped advance novel SARS-CoV-2 testing strategies. In addition, we have advanced the use of artificial intelligence tools in patient care and explored technologies to enhance the removal of protein-bound uremic solutes.

 

PATIENTS NATIONWIDE TO BENEFIT FROM STATE-OF-ThE-ART LAB


In 2021, Spectra Laboratories opened a new 200,000-square-foot laboratory in Southaven, Mississippi. At Spectra’s new build-to-suit facility, employees conduct comprehensive testing, analysis, and reporting to ensure the best possible care and outcomes for patients. The new state-of-the art facility is the company’s largest laboratory and will create more than 300 jobs over the next several years, providing the capacity to serve more patients.

LEARN MORE

 

INVESTING IN INNOVATION


Fresenius Medical Care Ventures invests in start-ups and early stage companies in the healthcare sector. The investments are targeted to support Fresenius Medical Care’s corporate strategy to grow continuously in our core business and to expand into new business areas. Fresenius Medical Care Ventures is complementing the corporate activities in external innovation.

LEARN MORE

 

RESEARCH FELLOWSHIP FOR NEW KIDNEY DISEASE TREATMENTS


To advance new research in kidney disease and to help find a cure, the American Society of Nephrology (ASN) established The Ben J. Lipps Research Fellowship as part of its KidneyCure Foundation. The fellowship is named after the former CEO of Fresenius Medical Care North America. Since its establishment in 2012, we have contributed $10 million and supported 35 unique studies. The program supports research over a two-year period, with five new fellowships funded annually. In 2021, the Ben J. Lipps Research Fellowship Program received 46 applications and awarded 10 new research fellowship grants. 

LEARN MORE

Awards and Recognition


All sustainability data is from Fresenius Medical Care North America for 2021 unless otherwise noted.

Read More